BG17795A3 - Метод за получаване на субституирани с арилпиперазинилалкил- аминоурацили-урацилетери-урацилитиоктер - Google Patents

Метод за получаване на субституирани с арилпиперазинилалкил- аминоурацили-урацилетери-урацилитиоктер

Info

Publication number
BG17795A3
BG17795A3 BG017051A BG1705170A BG17795A3 BG 17795 A3 BG17795 A3 BG 17795A3 BG 017051 A BG017051 A BG 017051A BG 1705170 A BG1705170 A BG 1705170A BG 17795 A3 BG17795 A3 BG 17795A3
Authority
BG
Bulgaria
Prior art keywords
uracylythiocter
uracylethers
aminouracyls
arylpiperazinylalkyl
substituted
Prior art date
Application number
BG017051A
Other languages
English (en)
Inventor
Wolfgang Pruesse
Kurt Klemm
Wolfgang Schoetensack
Original Assignee
Byk Gulden Lomberg Chemische Fabrik Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Byk Gulden Lomberg Chemische Fabrik Gmbh filed Critical Byk Gulden Lomberg Chemische Fabrik Gmbh
Publication of BG17795A3 publication Critical patent/BG17795A3/bg

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60Three or more oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Communication Cables (AREA)
BG017051A 1969-08-20 1970-08-19 Метод за получаване на субституирани с арилпиперазинилалкил- аминоурацили-урацилетери-урацилитиоктер BG17795A3 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE1942405A DE1942405C3 (de) 1969-08-20 1969-08-20 Arylsubstituierte Piperazinylpropylenaminouracile

Publications (1)

Publication Number Publication Date
BG17795A3 true BG17795A3 (bg) 1973-12-25

Family

ID=5743321

Family Applications (3)

Application Number Title Priority Date Filing Date
BG017052A BG17796A3 (bg) 1969-08-20 1970-08-15 Метод за получаване на субституирани с арилпиперазинилалкиламино- урацили,-урацилетер и урацилитиотер
BG017051A BG17795A3 (bg) 1969-08-20 1970-08-19 Метод за получаване на субституирани с арилпиперазинилалкил- аминоурацили-урацилетери-урацилитиоктер
BG015509A BG17585A3 (bg) 1969-08-20 1970-08-19 Метод за получаване на субституирани с арил пиперазинилалкиламино- урацили,урацилетер,урацилтиоетер

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BG017052A BG17796A3 (bg) 1969-08-20 1970-08-15 Метод за получаване на субституирани с арилпиперазинилалкиламино- урацили,-урацилетер и урацилитиотер

Family Applications After (1)

Application Number Title Priority Date Filing Date
BG015509A BG17585A3 (bg) 1969-08-20 1970-08-19 Метод за получаване на субституирани с арил пиперазинилалкиламино- урацили,урацилетер,урацилтиоетер

Country Status (24)

Country Link
US (2) US3957786A (bg)
AT (2) AT302359B (bg)
BE (1) BE755015A (bg)
BG (3) BG17796A3 (bg)
BR (1) BR6915466D0 (bg)
CA (1) CA956944A (bg)
CH (2) CH551990A (bg)
DE (1) DE1942405C3 (bg)
DK (1) DK124031B (bg)
ES (1) ES382842A1 (bg)
FI (1) FI54479C (bg)
FR (1) FR2073300B1 (bg)
GB (1) GB1309324A (bg)
HK (1) HK23678A (bg)
HU (1) HU163664B (bg)
IE (1) IE35177B1 (bg)
IL (1) IL35121A (bg)
LU (1) LU61527A1 (bg)
NL (1) NL155014B (bg)
NO (1) NO129148B (bg)
SE (1) SE386448B (bg)
SU (1) SU399130A3 (bg)
YU (2) YU36509B (bg)
ZA (1) ZA705729B (bg)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2329399A1 (de) * 1973-06-08 1975-01-02 Wuelfing J A Fa 4-alkyl-aminouracile, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
LU74319A1 (bg) * 1976-02-09 1977-08-19
DE3326118A1 (de) 1982-08-02 1984-02-09 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Pyridopyrimidintrione, verfahren zu ihrer herstellung, ihre verwendung und sie enthaltende arzneimittel
IE62890B1 (en) * 1988-12-06 1995-03-08 Hafslund Nycomed Pharma New piperazinylalkyl-3(2h)-pyridazinones process for the preparation thereof and the use thereof as agents lowering blood pressure
CA2024428A1 (en) * 1989-09-06 1991-03-07 Masayuki Ishikawa Agent for treating urinary obstruction
WO1991011185A1 (de) 1990-02-01 1991-08-08 Byk Gulden Lomberg Chemische Fabrik Gmbh Verwendung von urapidil und derivaten zur behandlung arteriosklerotische erkrankungen
DE4425143A1 (de) * 1994-07-15 1996-01-18 Basf Ag Substituierte Pyrimidinverbindungen und deren Verwendung
AU4302996A (en) * 1994-12-07 1996-06-26 Byk Gulden Lomberg Chemische Fabrik Gmbh Uracil derivatives
KR100639543B1 (ko) 1998-09-30 2006-10-31 다케다 야쿠힌 고교 가부시키가이샤 방광 배출력 개선제
US6864262B2 (en) * 2000-11-29 2005-03-08 Eli Lilly And Company 1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl) piperazine and pharmaceutically acceptable salts and solvents thereof
WO2003000664A1 (de) * 2001-06-22 2003-01-03 Bayer Aktiengesellschaft Uracilderivative und ihre verwendung bei der behandlung bakterieller erkrankungen
US20050059744A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
WO2005034998A2 (en) 2003-09-12 2005-04-21 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20050058696A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20060264442A1 (en) * 2005-05-18 2006-11-23 Allergan, Inc. Methods for the treatment of ocular and neurodegenerative conditions in a mammal
CN101200451B (zh) * 2006-12-15 2010-12-15 重庆药友制药有限责任公司 一种盐酸乌拉地尔的制备方法
CN102295607B (zh) * 2011-06-16 2013-04-17 郑州大学 乌拉地尔的逆相转移催化制备方法
CN116082250A (zh) * 2021-11-05 2023-05-09 江苏润安制药有限公司 一种新的制备盐酸乌拉地尔的方法
KR102638538B1 (ko) 2021-12-28 2024-02-20 주식회사 한서켐 우라피딜 제조 중간체의 제조방법
CN115477616A (zh) * 2022-09-27 2022-12-16 河北广祥制药有限公司 一种乌拉地尔杂质的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2567651A (en) * 1951-09-11 J-dialkyl-g-amino-l

Also Published As

Publication number Publication date
CH551990A (de) 1974-07-31
ES382842A1 (es) 1973-02-16
US4067982A (en) 1978-01-10
FR2073300B1 (bg) 1974-02-01
BG17585A3 (bg) 1973-11-10
LU61527A1 (bg) 1971-06-22
YU36509B (en) 1984-02-29
NL7012364A (bg) 1971-02-23
IE35177B1 (en) 1975-12-10
FI54479C (fi) 1978-12-11
FR2073300A1 (bg) 1971-10-01
CH582173A5 (bg) 1976-11-30
DK124031B (da) 1972-09-04
IL35121A (en) 1974-03-14
DE1942405B2 (de) 1973-10-31
ZA705729B (en) 1972-03-29
IL35121A0 (en) 1970-10-30
DE1942405A1 (de) 1971-09-16
NO129148B (bg) 1974-03-04
US3957786A (en) 1976-05-18
CA956944A (en) 1974-10-29
GB1309324A (en) 1973-03-07
BE755015A (fr) 1971-02-01
HU163664B (bg) 1973-10-27
HK23678A (en) 1978-05-12
AT318651B (de) 1974-11-11
BG17796A3 (bg) 1973-12-25
FI54479B (fi) 1978-08-31
YU207670A (en) 1982-02-25
SU399130A3 (bg) 1973-09-27
DE1942405C3 (de) 1974-05-30
NL155014B (nl) 1977-11-15
YU36518B (en) 1984-02-29
IE35177L (en) 1971-02-20
AT302359B (de) 1972-10-10
YU203979A (en) 1982-02-25
BR6915466D0 (pt) 1973-05-15
SU363248A3 (bg) 1972-12-30
SE386448B (sv) 1976-08-09

Similar Documents

Publication Publication Date Title
SE414497B (sv) Forfarande for framstellning av p-karbonyloxim-fenoxialkyl-karboxamider
BG17795A3 (bg) Метод за получаване на субституирани с арилпиперазинилалкил- аминоурацили-урацилетери-урацилитиоктер
BG20359A3 (bg) Метод за получаване на субституирани n-алил-2-ариламино- имидазолини -(2)
BG18599A3 (bg) Метод за получаване на бета-арил-2-аминоалкоксистироли
BG17749A3 (bg) Метод за получаване на фенокси-2-хидрокси -3- циклоалкиламинопропани
BG20582A3 (bg) Метод за получаване на р-халоген-фенил-2-пиромидинони
SU505349A3 (ru) Способ получени нафтилалкиламинов
BG17802A3 (bg) Метод за получаване на диалиламиноалканоиламиди
BG18603A3 (bg) Метод за непрекъснато получаване на циклохексаноноксим
BG19133A3 (bg) Метод за получаване на 1-фенил-2-хидрокси-3-хидроксилалкиламинопропани
BG17773A3 (bg) Метод за получаване на аминоалкилпиролидини
BG16738A3 (bg) Метод за получаване на анимиди на 3-ацил-р-резорциновата киселина
BG16333A3 (bg) Метод за получаване на гама-цианбутиралдимини
BG20585A3 (bg) Метод за получаване на заместени n-хидрокси-алкил-2-ариламино-имидазолини
BG17808A3 (bg) Метод за получаване на нови производни на тиетина
BG17524A3 (bg) Метод за получаване на производни на адамантилкарбоксалим дофеналоцетна киселина
BG17531A3 (bg) Метод за получаване на алкиламинопропани
BG17602A3 (bg) Метод за получаване на тетрахидро- бензо - диазепани
BG17625A3 (bg) Метод за получаане на нови съединения на полиацилокса- ламидразони
BG17962A3 (bg) Метод за получаване на нови производни на р- аминоал- кил- бензолсулфо- намида
BG17817A3 (bg) Метод за получаване на политерефталоило-ксаламидразон
BG16185A3 (bg) Метод за получаване на 1-алкил-2-аминометилпиролидини
SU439994A3 (ru) Способ получения 11-дезацетокси-вортманнина
BG16446A3 (bg) Метод за получаване на нови производни на р-аминоалкил-бензолсулфонамида
BG17609A3 (bg) Метод за получаване на нови производни на 21- дезодихидро- аймалина